Houston AI data firm partners on Alzheimer’s clinical trial

now testing

The trial, known as ADO2, will utilize OmniScience's recently developed product, Vivo, which uses generative AI to centralize and analyze clinical trial data in real time. Photo omniscience.bio

Houston data science firm OmniScience announced this month that it has partnered with Florida-based INmune Bio (NASDAQ: INMB) on a global Phase 2 Alzheimer’s disease clinical trial.

The trial, known as ADO2, will utilize OmniScience's recently developed product, Vivo, which uses generative AI to centralize and analyze clinical trial data in real time, according to a release. The two companies also partnered during Vivo’s development and recent roll-out.

"OmniScience and INmune Bio share a vision to transform how clinical trial teams engage with data – transforming data into knowledge in real time and informing decisions that increase the probability of success,” Angela Holmes, CEO of OmniScience, says in a statement. “As our partnership moves forward, we’re gaining further insights from the INmune team that we can integrate into Vivo’s roadmap. We look forward to our continued mutual success.”

The ADO2 trial will investigate INmune Bio's clinical-stage biotechnology XPro in patients with mild cognitive impairment or Alzheimer’s disease with brain inflammation, according to its website. Its products are focused on "restoring function in the body's innate immune system to fight disease."

The trial is overenrolled with 208 patients diagnosed with mild Alzheimer’s disease or mild cognitive impairment. The top-line results are expected to be released in Q2 2025.

"A global trial of this size is vast, and Vivo will be critical in our ability to analyze cognitive results,” Tara Lehner, INmune Bio’s vice president of clinical operations, says in the statement. “With genAI provided by Vivo, we can amplify our clinical teams’ capabilities, turning complex data into actionable insights at unprecedented speed, which means we can get answers—and treatments—to patients faster.”

INmune will be able to use OmniScience's Vivo product to unify data from electronic data capture, clinical trial management systems, patient-reported outcomes, clinical outcome assessments, labs, wearables, safety databases and more, according to the statement. The product has been shown to improve data quality and visualizations and reduce the reliance on spreadsheet-based data analysis during clinical trials.

Omniscience was originally founded in 2017, then known as Mercury Data Science. It rebranded and changed its name earlier this year. Holmes was named CEO in 2022.

Omniscience's Vivo product recently won first place in the CNS Summit 2024 Innovation Showcase in Boston and the Blue Whale Ribbon at the inaugural Whale Tank pitch competition during the 2024 Innovation Network Gathering (ING) in West Chester, Pennsylvania.

From Your Site Articles
Coya Therapeutics is looking into how a trendy weight loss drug could complement its Alzheimer’s disease treatment. Photo via Getty Images

Houston therapeutics innovator looks into GLP-1 drugs for Alzheimer’s treatment

drug discovery

Glucagon-like peptide 1, or GLP-1, agonists are all the rage right now thanks to drugs like Ozempic and Wegovy. Though they’re currently being prescribed for diabetes and weight loss, a Houston company reports that it may have found another use for GLP-1s.

Coya Therapeutics, a publicly traded clinical-stage biotechnology company, has filed intellectual property protection for a combination of its proprietary COYA 301 and GLP-1. Coya’s team believes that combining COYA 301, a low-dose interleukin-2 (IL-2) intended to enhance the anti-inflammatory function of regulatory T cells (Tregs), with GLP-1 could be a game-changer in the fight against Alzheimer’s disease.

How does GLP-1 amplify the positive results already noted for COYA 301? The company will soon release phase 2 data for IL-2 in patients with Alzheimer's. Through distinct mechanisms, the pair of drugs could synergistically combat inflammation. That means that neurodegenerative maladies such as Alzheimer’s are just the beginning. The drug combination could also fight autoimmune and metabolic conditions. This isn’t the first combination therapy for Coya — Coya 302 is a pairing of LD IL-2 and CTLA-4 Ig that has also racked up some success in human trials.

According to Coya’s CEO, Howard Berman, “We believe that combination immunotherapy approaches will evolve to play a meaningful role in treating complex immune-based diseases that are driven by a host of pathophysiologic mechanisms.”

He goes on to add that the company has already had success with targeting “multiple, independent, and non-overlapping immune pathways simultaneously” with COYA 302, a combination of COYA 301 and CTLA-4 Ig, commercially known as Abatacept. That pairing is currently being evaluated in numerous neurodegenerative disease models, such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s, and Parkinson’s diseases.

“We will continue to expand our portfolio with additional synergistic drug combinations with COYA 301,” Berman adds.

The Belfer family, led by oil tycoon Robert Belfer, had donated an additional $20 million to the Belfer Neurodegeneration Consortium. Photo via mdanderson.org

$20M donation drives neurodegeneration research in Houston

big impact

Neurodegeneration is one of the cruelest ways to age, but one recent donation is invigorating research with the goal of eradicating diseases like Alzheimer’s.

This month, Laurence Belfer announced that his family, led by oil tycoon Robert Belfer, had donated an additional $20 million to the Belfer Neurodegeneration Consortium, a multi-institutional initiative that targets the study and treatment of Alzheimer’s disease.

This latest sum brings the family’s donations to BNDC to $53.5 million over a little more than a decade. The Belfer family’s recent donation will be matched by institutional philanthropic efforts, meaning BNDC will actually be $40 million richer.

BNDC was formed in 2012 to help scientists gain stronger awareness of neurodegenerative disease biology and its potential treatments. It incorporates not only The University of Texas MD Anderson Cancer Center, but also Baylor College of Medicine, Massachusetts Institute of Technology (MIT) and Icahn School of Medicine at Mount Sinai.

It is the BNDC’s lofty objective to develop five new drugs for Alzheimer’s disease and related disorders over the next 10 years, with two treatments to demonstrate clinical efficacy.

“Our goal is ambitious, but having access to the vast clinical trial expertise at MD Anderson ensures our therapeutics can improve the lives of patients everywhere,” BNDC Executive Director Jim Ray says in a press release. “The key elements for success are in place: a powerful research model, a winning collaborative team and a robust translational pipeline, all in the right place at the right time.”

It may seem out of place that this research is happening at MD Anderson, but scientists are delving into the intersection between cancer and neurological disease through the hospital’s Cancer Neuroscience Program.

“Since the consortium was formed, we have made tremendous progress in our understanding of the molecular and genetic basis of neurodegenerative diseases and in translating those findings into effective targeted drugs and diagnostics for patients,” Ray continues. “Yet, we still have more work to do. Alzheimer's disease is already the most expensive disease in the United States. As our population continues to age, addressing quality-of-life issues and other challenges of treating and living with age-associated diseases must become a priority.”

And for the magnanimous Belfer family, it already is.

Houston Methodist's Nantz National Alzheimer Center received a $1 million donation to continue research in neurodegenerative diseases. Photo via Houston Methodist

Houston hospital snags $1M to advance Alzheimer’s research

money moves

Thanks to a recent donation, Houston Methodist is setting up an endowment to support research in neurodegenerative diseases.

Susan and William “Dub” Henning, Jr. have committed to a $1 million gift to Houston Methodist to support Alzheimer’s research at the Nantz National Alzheimer Center at the hospital. This gift will be used to create the Susan and William Henning Jr. Neurodegenerative Research Endowment and in response, a NNAC family room will be named in memory of Dub’s parents, Lena and William Henning.

“Knowing the impact that Alzheimer’s can have not only on patients, but also on the immediate and extended family members experiencing the disease inspired us to support the work being done at the Nantz National Alzheimer Center,” says Dub Henning in a news release. “We want to give hope to families struggling with this disease and contribute to ultimately finding a cure.”

Every year, the NNAC — led by Joseph C. Masdeu — treats thousands of patients looking to prevent Alzheimer’s disease, slow memory loss progression, and improve their quality of life. In 2021 alone, the center provided more than 4,000 patient visits. The fresh funding will allow for Dr. Masdeu's research projects — including more than 26 current studies, 14 in clinical trials and 12 studies to clarify the nature of diseases causing dementia — to continue the important work.

“One of our clinical trials will determine the effects of exercise in preventing deposits of amyloid and tau, two of the proteins that accumulate in the brain of people living with Alzheimer’s disease, and we’re also exploring the role of proper sleep in disease development,” says Masdeu in the release. “Among other studies, we are collaborating with Baylor College of Medicine to define genetic and chemical factors predisposing to the accumulation of amyloid and tau in the brain of people at all stages of the Alzheimer’s spectrum.

"These promising developments would not be possible without the compassion and generosity of community supporters like the Henning family," he continues.

Susan and William “Dub” Henning, Jr. gave a $1 million gift to Houston Methodist. Photo courtesy of Houston Methodist

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston sportstech startup shoots, scores in Pharrell Williams competition

on the rebound

Anyone who's witnessed even just a minute of basketball knows how important accuracy is in sinking shots on the court. One Houston startup has developed a device to help practice make perfect in a game.

GRIND’s portable basketball shooting machine, the first of its kind, created by founder and CEO Thomas Fields, former basketball phenom at Houston’s Reagan High School (now since renamed Heights High School).

“I remember being on varsity as a freshman and shooting thousands of shots every day trying to be the best,” says Fields. “My school bought a shooting machine, but they never let me use it. It was a game-changing piece of equipment, and I didn’t even have access because the gyms were always closed or closing.

“And another major problem was getting your rebounds, so we set out to make a portable basketball rebounding machine, so you could take it anywhere like home, the park, or the gym. It was also important to make it affordable, too.”

The GRIND shooting machine is available online. Photo via grindbasketball.com

At just 110 pounds, the GRIND shooting machine is 54 percent lighter than other home shooting machines, has 12-foot net, and needs just 90 seconds to set up or take down.

“Our portable shooting machine has been on the market for about three, four years now,” says Fields. “So now it's time to kind of accelerate the growth and that’s pretty exciting. We really have our sights on NBA Africa for a partnership there. Another one is Adidas, we are collaborating with them right now and they're also one of the sponsors of Black Hat Mission. And hopefully, we would like to land some NBA guys to invest and really get behind our sports tech company, but also make a significant impact in the community by getting kids into tech through sports.”

To that end, GRIND recently won second place in a competition from Black Ambition, an organization founded by Pharrell Williams. With the tagline, “Uninterrupted ambition. Unmatched impact,” the Black Ambition Prize celebrates underrepresented founders globally.

“When I initially heard of Black Ambition, I just kind of heard that Pharrell had started a venture fund aimed at uplifting black and brown entrepreneurs,” says Fields. “And when I read more about it, I realized that their mission perfectly aligned with GRIND. Our goal is to try to get kids into tech and STEM but use sports as the conduit and the bridge to get them there.

“We applied for the million-dollar cash prize for first place, but took second place, which is a $250,000 investment in the company. So now that Pharrell and Black Ambition are behind us, we are going out and raising some more capital to hit that hyper stage that we're going into. We are launching our software next year and our hardware has really been growing.”

Fields pitched GRIND on Shark Tank in May of 2021, where he was offered a joint deal for $250,000 for 25 percent of the company from both Mark Cuban and Barbara Corcoran. While Fields agreed on the show, the finalized terms of the deal were not disclosed.

- YouTubeThomas Fields is seeking $250000 for a 5% stake of GRIND. From Season 12 Episode 23 Watch Now: ...

As a startup, GRIND, a consumer brand developing the world’s first smart ecosystem of sports equipment products, represents the continued uptick with sportstech innovation in Houston.

“We want to revolutionize the world of sports equipment by leveraging cutting edge technology by developing sports equipment that can seamlessly connect to software, enhancing athletic performance, and pushing athletes to achieve their peak potential,” Fields says.

As GRIND continues to push forward and expand its footprint, it’s also looking to expand its customer base.

“I think the target users are middle school and high school athletes,” says Fields. “These are the kids that are striving to be great athletes and striving to get into college. We also have colleges that have our product as well. But mostly, the customer is the parents of those athletes. That's really who we're trying to get excited.

“And then, of course, there are the coaches and trainers. They own gyms, they own organizations and need equipment for their schools and universities. That's another target customer of ours for sure.”

Ultimately, GRIND will continue to build on Fields’ initial inspiration to design products and technologies with the athletes—especially hoopers—in mind.

“Our goal in the next few years is to really amp up the scholarships that we facilitate to funnel kids into STEM tech careers and pathways,” says Fields. “GRIND Day, which is a proclamation the City of Houston gave us for August 12th each year, is a day where we bring sports, tech, and culture all under one umbrella. Kids see us using 3D printers and lasers to cut the products that we make in our warehouse, which is in an underserved community, which hopefully makes them think it’s cool and want to get into technology.”

Houston airport cut traffic congestion by 99 percent during peak travel season

A Soaring Improvement

Years of physical improvements and other initiatives paid off this holiday season at George Bush Intercontinental Airport (IAH). Despite seeing a record number of flyers, traffic congestion at the airport dropped by an astounding amount.

“Our goal was to deliver a seamless journey during one of the busiest travel seasons of the year,” said Jim Szczesniak, director of aviation for Houston Airports. “The results show that our investments in infrastructure, technology and customer service are paying off. We are proud of our team and the traveling public for working together to make this holiday season a success. Our coordinated efforts between Houston Airports and Houston Police kept traffic flowing smoothly at our departure curbs while passengers followed instructions and used cell phones lots effectively. These efforts, paired with infrastructure improvements like the new International Arrivals Curb and expanded Terminal C garage entrance, demonstrate our commitment to delivering world-class service and efficiency.”

The holiday flying season officially lasts from December 20 to January 6. Data from Houston airports shows that between December 20 and December 30, 1.7 million passengers passed through IAH, a 21 percent increase over the same period in 2023. However, the number of heavy traffic periods fell 90 percent and periods of severe traffic fell 99 percent. To put it another way, passengers at IAH spent 4.4 hours in severe traffic during Christmas 2023. This past Christmas, it was just 2 minutes, an astounding reduction.

This was accomplished with the long-awaited new IAH International Arrivals Curb, which opened for public use on December 14. The new arrivals curb features seven lanes for dedicated drop-off and pick-up, greatly increasing the places for passengers to enter and exit the airport. IAH also opened the previously closed entry roadway lane before Thanksgiving, further reducing traffic snarl.

For those leaving their cars at the airport, a new cashless, automated system was built at HAS garages and ecoparks. New curbside agents were also hired, and Houston police helped direct traffic during the stressful and busy time.

“Our focus is always on providing a safe, stress-free experience,” said Kelly Woodward, chief operating officer for Houston Airports. “These upgrades allowed us to accommodate record passenger numbers while keeping traffic flowing. It’s a win for travelers and our city.”

IAH will continue to improve in 2025 as the new International Central Processor terminal comes fully online. As IAH becomes one of the main Gateways to Latin and South America, it will continue to serve the increasing number of flyers heading south of the border. Some time in 2025, 11 new lanes will open on the upper level, keeping traffic moving briskly.

---

This story originally appeared on our sister site, CultureMap.com.

Houston construction tech tool acquires Y Combinator-backed co.

M&A moves

A Houston-based platform that connects skilled electricians with top electrical contractors has made a strategic acquisition.

Buildforce announced it has acquired Ladder, which is a Y Combinator-backed, technology-enabled construction labor marketplace.

The acquisition is part of Buildforce’s expansion plans into the southeastern U.S. and during a time of increased demand for skilled construction talent. Buildforce will work to leverage the Ladder customer base of over 200 customers across six states, as well as its extensive electrician network of over 10,000 pre-screened electricians, which is the largest in the Southeast.

In addition to expanding to Georgia with the Ladder acquisition, Buildforce launched in Arizona in October and will expand into several additional high-construction volume states in 2025. Also in October, Buildforce launched an easier product to manage a flexible time approval process with its Activity Log and Comments for Time Entries update. Contractors in these regions will be introduced to a more “integrated, technology-driven approach to talent acquisition and workforce management that drives efficiency and delivers higher quality project outcomes,” according to Buildforce.

“There are two major problems plaguing the construction labor market,” Moody Heard, co-founder and CEO of Buildforce, says in a news release. “One, the project-based nature of construction work means tradesmen are constantly ‘working themselves out of a job’, meaning high employee turnover. And two, the industry is experiencing a secular decline in the supply of tradesmen relative to surging demand.”

Ladder Founder and CEO Alex Stewart will continue on in a leadership role as a senior executive with Buildforce.

"I am incredibly excited to join the Buildforce team to further its expansion into new markets, while staying true to its mission of helping people in the construction trades find more security and fulfillment,” Stewart said in a news release. “Buildforce is at the forefront of workforce management for the construction industry, and I look forward to working with Moody and the rest of the talented Buildforce team to drive the business towards continued growth.”

Buildforce was founded in 2019 to help close the gap in the construction labor market that affected skilled tradespeople and contractors. In 2021, the company raised a $4 million round backed by Houston-based Mercury.

View All Listings